Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 359

1.

Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure.

Borghetti A, Moschese D, Cingolani A, Baldin G, Speziale D, Ciccullo A, Lombardi F, Emiliozzi A, Belmonti S, Antinori A, Cauda R, Di Giambenedetto S.

HIV Med. 2019 Jun 25. doi: 10.1111/hiv.12759. [Epub ahead of print]

PMID:
31240860
2.

The role of procalcitonin outside of the Intensive Care Unit (ICU): a multidisciplinary approach.

Fantoni M, Taddei E, Cauda R, Antonelli Incalzi R, Capone A, Cortese F, Sanguinetti M, Spandonaro F, Urbani A, Murri R.

Eur Rev Med Pharmacol Sci. 2019 Apr;23(7):2978-2985. doi: 10.26355/eurrev_201904_17579.

3.

Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum β-lactamase-producing Enterobacteriaceae infections.

Tacconelli E, Cataldo MA, Mutters NT, Carrara E, Bartoloni A, Raglio A, Cauda R, Mantengoli E, Luzzaro F, Pan A, Beccara LA, Pecile P, Tinelli M, Rossolini GM.

Int J Antimicrob Agents. 2019 Jul;54(1):49-54. doi: 10.1016/j.ijantimicag.2019.04.007. Epub 2019 Apr 12.

PMID:
30986523
4.

A pilot experience of common European infectious diseases curriculum for medical students: the IDEAL summer school.

Charlier C, Wolf FI, Vlieghe E, Planquette B, Damme PV, Gaetano K, Buffet P, Henry B, Cevik M, Leen C, Laurenson I, Cameron H, Ogavu J, Nabankema E, Omona V, Valnaud P, Mackintosh C, Johannessen I, Geertruyden JV, Jeunne CL, Cauda R.

Future Microbiol. 2019 Mar;14:369-372. doi: 10.2217/fmb-2019-0037. Epub 2019 Mar 22. No abstract available.

PMID:
30900924
5.

Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016.

Bellino S, Borghetti A, Lombardi F, Camoni L, Ciccullo A, Baldin G, Belmonti S, Moschese D, Lamonica S, Cauda R, Pezzotti P, Di Giambenedetto S.

Epidemiol Infect. 2019 Jan;147:e89. doi: 10.1017/S0950268819000098.

6.

Liver fibrosis is associated with cognitive impairment in people living with HIV.

Ciccarelli N, Fabbiani M, Brita AC, De Marco R, Grima P, Gagliardini R, Borghetti A, Cauda R, Di Giambenedetto S.

Infection. 2019 Feb 19. doi: 10.1007/s15010-019-01284-8. [Epub ahead of print]

PMID:
30784024
7.

Use of procalcitonin as a tool for antibiotic stewardship.

Murri R, Taddei E, Cauda R, Fantoni M.

Future Microbiol. 2019 Jan;14:77-79. doi: 10.2217/fmb-2018-0326. Epub 2019 Jan 15. No abstract available.

8.

Performance evaluation of the (1,3)-β-D-glucan detection assay in non-intensive care unit adult patients.

Murri R, Camici M, Posteraro B, Giovannenze F, Taccari F, Ventura G, Scoppettuolo G, Sanguinetti M, Cauda R, Fantoni M.

Infect Drug Resist. 2018 Dec 20;12:19-24. doi: 10.2147/IDR.S181489. eCollection 2019.

9.

Risk factors for recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypes.

Falcone M, Tiseo G, Iraci F, Raponi G, Goldoni P, Delle Rose D, Santino I, Carfagna P, Murri R, Fantoni M, Fontana C, Sanguinetti M, Farcomeni A, Antonelli G, Aceti A, Mastroianni C, Andreoni M, Cauda R, Petrosillo N, Venditti M.

Clin Microbiol Infect. 2019 Apr;25(4):474-480. doi: 10.1016/j.cmi.2018.06.020. Epub 2018 Jun 28.

PMID:
29964230
10.

Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.

Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C, Menichetti F, Viscoli C, Campoli C, Venditti M, De Gasperi A, Mularoni A, Tascini C, Parruti G, Pallotto C, Sica S, Concia E, Cultrera R, De Pascale G, Capone A, Antinori S, Corcione S, Righi E, Losito AR, Digaetano M, Amadori F, Giacobbe DR, Ceccarelli G, Mazza E, Raffaelli F, Spanu T, Cauda R, Viale P.

Clin Infect Dis. 2019 Jan 18;68(3):355-364. doi: 10.1093/cid/ciy492.

PMID:
29893802
11.

Procalcitonin is useful in driving the choice of early antibiotic treatment in patients with bloodstream infections.

Murri R, Mastrorosa I, Taccari F, Baroni S, Giovannenze F, Palazzolo C, Lardo S, Scoppettuolo G, Ventura G, Cauda R, Fantoni M.

Eur Rev Med Pharmacol Sci. 2018 May;22(10):3130-3137. doi: 10.26355/eurrev_201805_15072.

12.

Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.

Belmonti S, Lombardi F, Quiros-Roldan E, Latini A, Castagna A, Borghetti A, Baldin G, Ciccullo A, Cauda R, De Luca A, Di Giambenedetto S; ATLAS-M Study Group .

J Antimicrob Chemother. 2018 Jul 1;73(7):1949-1954. doi: 10.1093/jac/dky125.

PMID:
29788156
13.

Systematic clinical management of patients with candidemia improves survival.

Murri R, Giovannenze F, Camici M, Torelli R, Ventura G, Scoppettuolo G, Sanguinetti M, Cauda R, Fantoni M.

J Infect. 2018 Aug;77(2):145-150. doi: 10.1016/j.jinf.2018.03.011. Epub 2018 May 6.

PMID:
29742466
14.

Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.

Fabbiani M, Gagliardini R, Ciccarelli N, Quiros Roldan E, Latini A, d'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Del Pin B, Lombardi F, D'Avino A, Focà E, Colafigli M, Cauda R, Di Giambenedetto S, De Luca A; ATLAS-M Study Group .

J Antimicrob Chemother. 2018 Jul 1;73(7):1955-1964. doi: 10.1093/jac/dky123.

PMID:
29668978
15.

Multidisciplinary management of pyogenic spondylodiscitis: epidemiological and clinical features, prognostic factors and long-term outcomes in 207 patients.

Pola E, Taccari F, Autore G, Giovannenze F, Pambianco V, Cauda R, Maccauro G, Fantoni M.

Eur Spine J. 2018 Jun;27(Suppl 2):229-236. doi: 10.1007/s00586-018-5598-9. Epub 2018 Apr 17.

PMID:
29667140
16.

IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines.

Murri R, Taccari F, Palazzolo C, Fantoni M, Cauda R.

Clin Infect Dis. 2018 May 17;66(11):1815-1816. doi: 10.1093/cid/cix1114. No abstract available.

PMID:
29272389
17.

A 72-h intervention for improvement of the rate of optimal antibiotic therapy in patients with bloodstream infections.

Murri R, Taccari F, Spanu T, D'Inzeo T, Mastrorosa I, Giovannenze F, Scoppettuolo G, Ventura G, Palazzolo C, Camici M, Lardo S, Fiori B, Sanguinetti M, Cauda R, Fantoni M.

Eur J Clin Microbiol Infect Dis. 2018 Jan;37(1):167-173. doi: 10.1007/s10096-017-3117-2. Epub 2017 Oct 19.

PMID:
29052092
18.

Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection.

Giannella M, Trecarichi EM, Giacobbe DR, De Rosa FG, Bassetti M, Bartoloni A, Bartoletti M, Losito AR, Del Bono V, Corcione S, Tedeschi S, Raffaelli F, Saffioti C, Spanu T, Rossolini GM, Marchese A, Ambretti S, Cauda R, Viscoli C, Lewis RE, Viale P, Tumbarello M; Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva (ISGRI-SITA).

Int J Antimicrob Agents. 2018 Feb;51(2):244-248. doi: 10.1016/j.ijantimicag.2017.08.019. Epub 2017 Aug 24.

PMID:
28842283
19.

3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.

Gagliardini R, Bandera A, Zaccarelli M, Sterrantino G, Latini A, D'Avino A, Lapadula G, Antinori A, Cauda R, De Luca A, Gori A, Di Giambenedetto S, Fabbiani M.

Antivir Ther. 2018;23(2):139-148. doi: 10.3851/IMP3188.

PMID:
28799920
20.

Antibiotic stewardship from toolkit to local implementation: the 'gutta cavat lapidem' strategy.

Fantoni M, Murri R, Cauda R.

Future Microbiol. 2017 Sep;12:935-938. doi: 10.2217/fmb-2017-0110. Epub 2017 Jul 26. No abstract available.

PMID:
28745516
21.

Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin.

Manna R, Cauda R, Feriozzi S, Gambaro G, Gasbarrini A, Lacombe D, Livneh A, Martini A, Ozdogan H, Pisani A, Riccio E, Verrecchia E, Dagna L; International Panel for RAre recurrent FUO-IPRAFUO.

Intern Emerg Med. 2017 Oct;12(7):1059-1067. doi: 10.1007/s11739-017-1704-y. Epub 2017 Jul 19.

PMID:
28726033
22.

Antibodies against a β-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients.

Torosantucci A, Tumbarello M, Bromuro C, Chiani P, Posteraro B, Sanguinetti M, Cauda R, Cassone A.

Sci Rep. 2017 Jun 2;7(1):2722. doi: 10.1038/s41598-017-02977-6.

23.

Answer to the Letter to the Editor of S. Huang et al. concerning "New classification for the treatment of pyogenic spondylodiscitis: validation study on a population of 250 patients with a follow-up of 2 years" by Enrico Pola et al. Eur Spine J (2017) doi:10.1007/s00586-017-5043-5.

Pola E, Autore G, Formica VM, Pambianco V, Colangelo D, Cauda R, Fantoni M.

Eur Spine J. 2017 Sep;26(9):2476-2477. doi: 10.1007/s00586-017-5162-z. Epub 2017 May 30. No abstract available.

PMID:
28560491
24.

International infectious diseases teaching to undergraduate medical students: A successful European collaborative experience.

Charlier C, Johannessen I, Mackintosh CL, Wilks D, Cauda R, Wolf FI, Le Jeunne C.

Med Teach. 2017 Sep;39(9):981-986. doi: 10.1080/0142159X.2017.1332364. Epub 2017 May 27.

PMID:
28552022
25.

Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.

Lombardi F, Belmonti S, Quiros-Roldan E, Latini A, Castagna A, D'Ettorre G, Gagliardini R, Fabbiani M, Cauda R, De Luca A, Di Giambenedetto S; AtLaS-M Study Group.

J Antimicrob Chemother. 2017 Jul 1;72(7):2055-2059. doi: 10.1093/jac/dkx068.

PMID:
28333353
26.

New classification for the treatment of pyogenic spondylodiscitis: validation study on a population of 250 patients with a follow-up of 2 years.

Pola E, Autore G, Formica VM, Pambianco V, Colangelo D, Cauda R, Fantoni M.

Eur Spine J. 2017 Oct;26(Suppl 4):479-488. doi: 10.1007/s00586-017-5043-5. Epub 2017 Mar 21.

PMID:
28324216
27.

Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries?
.

Cattaneo D, Andreoni M, Carosi G, Cauda R, Lazzarin A, Rizzardini G.

Int J Clin Pharmacol Ther. 2017 May;55(5):381-393. doi: 10.5414/CP202775. Review.

PMID:
28211784
28.

Trimethoprim-sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series.

Murri R, Fiori B, Spanu T, Mastrorosa I, Giovannenze F, Taccari F, Palazzolo C, Scoppettuolo G, Ventura G, Sanguinetti M, Cauda R, Fantoni M.

Infection. 2017 Apr;45(2):209-213. doi: 10.1007/s15010-016-0968-x. Epub 2017 Feb 9.

PMID:
28185222
29.

Characteristics of Staphylococcus aureus Bacteraemia and Predictors of Early and Late Mortality.

Bassetti M, Peghin M, Trecarichi EM, Carnelutti A, Righi E, Del Giacomo P, Ansaldi F, Trucchi C, Alicino C, Cauda R, Sartor A, Spanu T, Scarparo C, Tumbarello M.

PLoS One. 2017 Feb 2;12(2):e0170236. doi: 10.1371/journal.pone.0170236. eCollection 2017.

30.

Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).

Di Giambenedetto S, Fabbiani M, Quiros Roldan E, Latini A, D'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Di Pietro M, Mondi A, Ciccarelli N, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R; Atlas-M Study Group.

J Antimicrob Chemother. 2017 Apr 1;72(4):1163-1171. doi: 10.1093/jac/dkw557.

PMID:
28093483
31.

Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients.

Borghetti A, Baldin G, Capetti A, Sterrantino G, Rusconi S, Latini A, Giacometti A, Madeddu G, Picarelli C, De Marco R, Cossu MV, Lagi F, Cauda R, De Luca A, Di Giambenedetto S; Odoacre Study Group.

AIDS. 2017 Jan 28;31(3):457-459. doi: 10.1097/QAD.0000000000001357. No abstract available.

PMID:
28079545
32.

Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients.

Gagliardini R, Fabbiani M, Colafigli M, D'Avino A, Mondi A, Borghetti A, Lamonica S, Cauda R, De Luca A, Di Giambenedetto S.

J Chemother. 2017 Oct;29(5):299-307. doi: 10.1080/1120009X.2016.1269040. Epub 2016 Dec 26.

PMID:
28019192
33.

Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment.

Lapadula G, Bernasconi DP, Casari S, Maggiolo F, Cauda R, Di Pietro M, Ladisa N, Sighinolfi L, Dal Zoppo S, Sabbatini F, Soria A, Pezzoli C, Mondi A, Costarelli S, Valsecchi MG, Torti C, Gori A; Italian MASTER cohort.

PLoS One. 2016 Sep 15;11(9):e0162320. doi: 10.1371/journal.pone.0162320. eCollection 2016.

34.

Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.

Fabbiani M, Di Giambenedetto S, Poli A, Borghetti A, Castagna A, Mondi A, Galizzi N, Maillard M, Gori A, Cauda R, De Luca A, Gianotti N.

J Infect. 2016 Dec;73(6):619-623. doi: 10.1016/j.jinf.2016.08.011. Epub 2016 Aug 26. No abstract available.

PMID:
27575581
35.

Nursing home residence is associated with spread of Clostridium difficile ribotype 027 in central Italy.

Falcone M, Iraci F, Raponi G, Goldoni P, Belvisi V, Delle Rose D, Santino I, Murri R, Fantoni M, Carfagna P, Sanguinetti M, Fontana C, Farcomeni A, Tiseo G, Aceti A, Cauda R, Vullo V, Mastroianni CM, Andreoni M, Venditti M.

J Hosp Infect. 2016 Oct;94(2):201-3. doi: 10.1016/j.jhin.2016.06.024. Epub 2016 Jul 30. No abstract available.

PMID:
27546454
36.

Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study.

Lombardi F, Belmonti S, Fabbiani M, Borghetti A, Cauda R, De Luca A, Di Giambenedetto S.

J Antimicrob Chemother. 2016 Dec;71(12):3621-3622. Epub 2016 Aug 3. No abstract available.

PMID:
27494930
37.

Human Rickettsia aeschlimannii infection: first case with acute hepatitis and review of the literature.

Tosoni A, Mirijello A, Ciervo A, Mancini F, Rezza G, Damiano F, Cauda R, Gasbarrini A, Addolorato G; Internal Medicine Sepsis Study Group.

Eur Rev Med Pharmacol Sci. 2016 Jun;20(12):2630-3.

38.

Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS.

Ciccarelli N, Limiti S, Fabbiani M, Baldonero E, Milanini B, Lamonica S, Cauda R, Di Giambenedetto S, Silveri MC.

Appl Neuropsychol Adult. 2017 Sep-Oct;24(5):410-419. doi: 10.1080/23279095.2016.1189424. Epub 2016 Jun 13.

PMID:
27292092
39.

Impact of antibiotic stewardship on perioperative antimicrobial prophylaxis.

Murri R, de Belvis AG, Fantoni M, Tanzariello M, Parente P, Marventano S, Bucci S, Giovannenze F, Ricciardi W, Cauda R, Sganga G; collaborative SPES Group.

Int J Qual Health Care. 2016 Sep;28(4):502-7. doi: 10.1093/intqhc/mzw055. Epub 2016 Jun 9.

PMID:
27283440
40.

Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study.

Lombardi F, Belmonti S, Fabbiani M, Morandi M, Rossetti B, Tordini G, Cauda R, De Luca A, Di Giambenedetto S, Montagnani F.

PLoS One. 2016 Jun 3;11(6):e0156523. doi: 10.1371/journal.pone.0156523. eCollection 2016.

41.

Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE).

Milanini B, Ciccarelli N, Fabbiani M, Baldonero E, Limiti S, Gagliardini R, Borghetti A, D'Avino A, Mondi A, Colafigli M, Cauda R, Di Giambenedetto S.

Clin Neuropsychol. 2016 Jan-Dec;30(sup1):1457-1468. Epub 2016 May 16.

PMID:
27180611
42.

Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy.

Borghetti A, Baldin G, Ciccullo A, Gagliardini R, D'Avino A, Mondi A, Ciccarelli N, Lamonica S, Fanti I, Trecarichi E, Fabbiani M, Cauda R, De Luca A, Di Giambenedetto S.

J Antimicrob Chemother. 2016 Aug;71(8):2359-61. doi: 10.1093/jac/dkw147. Epub 2016 May 4. No abstract available.

PMID:
27147306
43.

Cognitive reserve and neuropsychological functioning in older HIV-infected people.

Milanini B, Ciccarelli N, Fabbiani M, Limiti S, Grima P, Rossetti B, Visconti E, Tamburrini E, Cauda R, Di Giambenedetto S.

J Neurovirol. 2016 Oct;22(5):575-583. Epub 2016 Mar 10.

PMID:
26965299
44.

A Murine, Bispecific Monoclonal Antibody Simultaneously Recognizing β-Glucan and MP65 Determinants in Candida Species.

Zito A, Bromuro C, Mandili G, Chiani P, Horenstein AL, Malavasi F, Cauda R, Cassone A, Torosantucci A.

PLoS One. 2016 Feb 9;11(2):e0148714. doi: 10.1371/journal.pone.0148714. eCollection 2016.

45.

Initial antifungal strategy does not correlate with mortality in patients with candidemia.

Murri R, Scoppettuolo G, Ventura G, Fabbiani M, Giovannenze F, Taccari F, Milozzi E, Posteraro B, Sanguinetti M, Cauda R, Fantoni M.

Eur J Clin Microbiol Infect Dis. 2016 Feb;35(2):187-93. doi: 10.1007/s10096-015-2527-2. Epub 2015 Dec 3.

PMID:
26634352
46.

Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine.

Belmonti S, Lombardi F, Morandi M, Fabbiani M, Tordini G, Cauda R, De Luca A, Di Giambenedetto S, Montagnani F.

J Immunoassay Immunochem. 2016;37(2):189-200. doi: 10.1080/15321819.2015.1106949.

PMID:
26506438
47.

Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort).

Torti C, Raffetti E, Donato F, Castelli F, Maggiolo F, Angarano G, Mazzotta F, Gori A, Sighinolfi L, Pan A, Cauda R, Scalzini A, Quiros-Roldan E, Nasta P, Gregis G, Benatti S, Digiambenedetto S, Ladisa N, Giralda M, Saracino A, Castelnuovo F, Di Pietro M, Lo Caputo S, Lapadula G, Costarelli S, Lorenzotti S, Mazzini N, Paraninfo G, Casari S, Focà E, Pezzoli C, Fabbiani M, Monno L, Pierotti P, Ble C, Leone S, Postorino MC, Fornabaio C, Zacchi F, Zoncada A, Carosi G.

Int J Epidemiol. 2017 Apr 1;46(2):e12. doi: 10.1093/ije/dyv192. No abstract available.

PMID:
26445966
48.

Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection.

Fabbiani M, Di Giambenedetto S, Cingolani A, Fanti I, Colafigli M, Tamburrini E, Cauda R, Navarra P, De Luca A, Murri R.

Infect Dis (Lond). 2016;48(1):48-55. doi: 10.3109/23744235.2015.1082034. Epub 2015 Sep 2.

PMID:
26329383
49.

Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study.

Giacobbe DR, Del Bono V, Trecarichi EM, De Rosa FG, Giannella M, Bassetti M, Bartoloni A, Losito AR, Corcione S, Bartoletti M, Mantengoli E, Saffioti C, Pagani N, Tedeschi S, Spanu T, Rossolini GM, Marchese A, Ambretti S, Cauda R, Viale P, Viscoli C, Tumbarello M; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva).

Clin Microbiol Infect. 2015 Dec;21(12):1106.e1-8. doi: 10.1016/j.cmi.2015.08.001. Epub 2015 Aug 14.

50.

Want a better way to control antibiotic resistance? Fight the corruption.

Cauda R, Cassone A.

Pathog Glob Health. 2015 Jun;109(4):168-9. doi: 10.1179/2047772415Z.000000000267. No abstract available.

Supplemental Content

Support Center